Alamar Biosciences Q2 2026 net loss widens to $13.2 million; revenue rises 82% to $29.4 million

Reuters2026/08/10 20:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Alamar Biosciences posted Q2 revenue of $29.4 million, up 82% year over year.
Net loss widened to $13.2 million; operating loss widened to $13.5 million.
Gross margin rose 7 percentage points to 60%, driven by manufacturing efficiencies for consumables and a shift toward high-margin consumables.
Consumable revenue more than doubled to $15.5 million; instrument revenue rose 35% to $7.8 million.
Forecast full-year 2026 revenue of $116 million-$120 million; launched an eMTBR-tau immunoassay and the NULISAseq Immune 340 Panel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alamar Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-342378), on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Alamar Biosciences Q2 2026 net loss widens to $13.2 million; revenue rises 82% to $29.4 million

You may also like

Crypto prices